AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03401723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Endoscopy Training System
Description: The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~1. Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~2. Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~3. Loop Management - The management of a standard alfa-loop.~4. Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal.
Study NCT03401723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D-Colonoscopy Retraction Score
Description: 3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
Study NCT02183909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement and retention for HIV-positive Y/MSM in care
Description: Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
Study NCT02183909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Engagement and retention for HIV-negative Y/MSM in sexual health services
Description: Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
Study NCT02183909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild PEP Substudy
Description: A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
Study NCT02554422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PalpEar
Description: Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
Study NCT04269434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Screening
Description: the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
Study NCT02928471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study NCT03694262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib 600mg orally twice daily by continuous dosing
Study NCT03694262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg IV on day 1 of every cycle
Study NCT03694262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1,200mg IV on day 1 of every cycle
Study NCT00429442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 80 mg once daily
Study NCT00429442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: calcium tablets once daily
Study NCT04223128 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided transversus abdominis plane block
Description: Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
Study NCT04223128 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided transversus abdominis plane block
Description: Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
Study NCT01292577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CET/PT
Description: CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
Study NCT01292577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
Study NCT03643913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).
Study NCT03643913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular block
Description: Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).
Study NCT03643913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Blocking Agents and reversing agents
Description: Deep neuromuscular block versus moderate neuromuscular block.
Study NCT03643913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents and reversing agents
Description: Deep neuromuscular block versus moderate neuromuscular block.
Study NCT03650296 — intervention group
Intervention type: DEVICE
Intervention: ePER vs PS vs PaedER
Description: see detailed description of methods
Study NCT04826133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 μg (three capsules of 0.5 μg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.
Study NCT04826133 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.
Study NCT01174810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28-days.
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ARA-C (LDAC)
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28 days.
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28 days
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin given using 60 mg/m2 for 3-days
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 100 mg/m2 on days 1 through 7
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
Study NCT01546038 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Low dose ARA-C (LDAC)
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Study NCT04587401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: normotensive patients
Description: patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range
Study NCT04587401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients with hypertension diagnosis
Description: Patients who have high blood pressure diagnosis
Study NCT04587401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients who do not know they are hypertensive but actual blood pressure is high
Description: patients with preoperative high blood pressure, who do not know they are hypertensive
Study NCT01511003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study NCT00231309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Granulocyte Colony Stimulating Factor
Description: Granulocyte Colony Stimulating Factor
Study NCT01827878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
Study NCT01827878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
Study NCT01827878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Study NCT01827878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Study NCT01411449 — intervention group
Intervention type: DRUG
Intervention: Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Description: Patients who will need to undergo contrast enhanced MRI with Primovist
Study NCT03919409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules
Study NCT01531595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus alternating XELOX/XELIRI
Description: 3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
Study NCT03919409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules
Study NCT04432116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality 1
Description: the subject is in a virtual waiting room, there is no other intervention. The principle of this intervention is to make the subject wait with as little interfering events as possible
Study NCT04432116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality 2
Description: Subjects are in a virtual environment mimicking a space ship. On the screen there is a red light and subjects wait for this red light to become green. They press on a pad each time the red light becomes green
Study NCT01819948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoMed™
Study NCT03427268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM060184
Description: PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle).
Study NCT01493700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heated circuit
Description: use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
Study NCT01493700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
Study NCT01857700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation for transport cost
Study NCT01857700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation for lost wages
Study NCT01857700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation for transport cost and lost wages
Study NCT01857700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
Study NCT05299619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel
Description: a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
Study NCT00287677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human Growth Hormone
Description: Growth Hormone during 6 months (30UG/KG/DAY)
Study NCT00287677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
Study NCT00287677 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination
Description: Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
Study NCT00287677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: HAART all over the trial
Study NCT03702491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
Study NCT01238393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab
Description: monthly injections x3 +/- 2nd series of 3
Study NCT01977183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSPrebiotic
Description: Potato Resistant Starch
Study NCT01977183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Corn Starch
Study NCT01167192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01167192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01167192 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT01167192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy (recommended but not mandatory)
Study NCT03632005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure
Description: Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
Study NCT03632005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sterile dressing
Description: Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
Study NCT04603833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680+Docetaxel
Description: Participants will receive SHR3680 combined with Docetaxel
Study NCT04603833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR3680
Description: Participants will receive SHR3680
Study NCT04603833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive Docetaxel
Study NCT00892944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516
Description: Fractionated single oral dose
Study NCT01163955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time to fatigue
Description: 5 minutes while playing video games
Study NCT03716388 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.
Study NCT03716388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.
Study NCT03716388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine Granules
Description: Mesalamine granules 4 grams a day
Study NCT03716388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Water with food grade colour to resemble fecal slurry
Study NCT03716388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo granules
Description: Granules resembling mesalamine granules, 4 grams a day
Study NCT00217022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 3 tablets daily
Study NCT00217022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: 9 mg daily (three tablets)
Study NCT06064370 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic adrenalectomy
Description: laparoscopic adrenalectomy for pheochromocytoma
Study NCT03788954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
Study NCT03788954 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
Study NCT03124550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame Experience
Description: Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
Study NCT01104064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real rTMS combined with constraint induced therapy
Description: 10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
Study NCT01104064 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS combined with constraint induced therapy
Description: 10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.